Comparative study of pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) injection and cisplatin in the treatment of colorectal cancer malignant ascites

doi:10.3877/cma.j.issn.2095-3224.2019.03.010

Abstract

Abstract:

Objective

Retrospective analysis to investigate the short-term curative effect and safety of pseudomonas aeruginosa-mannosesensitive hemagglutinin (PA-MSHA) and cisplatin in the treatment of malignant ascites of colorectal cancer.

Methods

A retrospective analysis was made on 49 patients with colorectal cancer whose abdominal B-mode ultrasonography proved to be moderate to large amount of peritoneal effusion and malignant ascites by cytological examination in the Fourth Hospital of Hebei Medical University. There are 31 patients in the PA-MSHA group and 18 patients in the cisplatin group. PA-MSHA: Intraperitoneally inject PA-MSHA 10 mL×10 in the first, third, and fifth day, 7 days a cycle, 2 cycles in total. Cisplatin group: Intraperitoneally inject cisplatin 50 mg/m² in the first day, 7 days a cycle, 2 cycles in total. The two groups were given mFOLFOX6 chemotherapy at the same time. The short-term efficacy was evaluated according to the WHO (1981) treatment criteria for malignant ascites. The quality of life was evaluated according to the Karnofsky score, and the adverse reactions during the treatment were evaluated.

Results

Among 31 cases in the PA-MSHA group, 19 cases were effective. Five cases in the cisplatin group were effective among 18 cases (χ²=5.118, P=0.024). The quality of life (QOL) of 22 patients were obviously improved in the PA-MSHA group, while 7 cases in the cisplatin group (χ²=6.586, P=0.01). The rate of fever is 38.71% in the PA-MSHA group and 11.11% (χ²=4.25, P=0.039) in the cisplatin group. There was 1 case (3.23%) of abdominal pain in the PA-MSHA group, six cases (33.33%)in the cisplatin group (χ²=8.43, P=0.004). There was no abdominal infection in the PA-MSHA group, and 2 cases (11.11%) of abdominal infection in the cisplatin group (χ²=3.591, P=0.058).

Conclusion

Intraperitoneal infusion of PA-MSHA is a safe and effective treatment for malignant ascites of colorectal cancer. It can achieve good short-term effect and improve the quality of life of patients. The effective rate in the PA-MSHA group is significantly higher than that in the cisplatin group.

Key words: Colorectal neoplasms, Malignant ascites, Immunotherapy, PA-MSHA, Cisplatin

Guanglin Wang, Feifei Wang, Zesong Meng, Guiying Wang. Comparative study of pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) injection and cisplatin in the treatment of colorectal cancer malignant ascites[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(03): 262-266.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.03.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I03/262

Figures/Tables 3

References 24

[1]	Siegel R, Naishandham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2]	Torre A, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CACancer J Clin, 2015, 65(2): 87-108.
[3]	万莉, 何耿劲. 铜绿假单胞注射液治疗恶性胸腔积液的临床观察[J]. 临床肺科杂志, 2013, 18(3): 401-402.
[4]	王浦华, 沈通一, 葛海燕. 铜绿假单胞菌制剂在恶性肿瘤中的辅助治疗作用[J].世界华人消化杂志, 2010, 18(30): 3171-3174.
[5]	宋飞雪, 裴霞霞, 金七妹, 等.铜绿假单胞菌注射液在恶性胸腔积液治疗中的疗效观察[J].中国肿瘤临床, 2013, 40(18): 1127-1129.
[6]	Teo M. Peritoneal-based malignancies and their treatment [J]. Ann Acad Med Singapore, 2010, 39: 54-57.
[7]	Storni F, Stirnimann G, Banz V, et al. Treatment of Malignant Ascites Using an Automated Pump Device [J]. Am J Gastroenterol, 2018, 113(7): 1060-1061.
[8]	Xia LJ, Wu YL, Ma J, et al. Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model [J]. Mol Med Rep, 2018, 17(5): 6245-6252.
[9]	Hanada R, Yokomichi N, Kato C, et al. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study [J]. Support Care Cancer, 2018, 26(5): 1489-1497.
[10]	Elias D, Mariani A, Cloutier AS, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin [J]. Eur J Surg Oncol, 2014, 40(11): 1467-1473.
[11]	Zitvogel L, Ma Y, Raoult D, et al.The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies [J]. Science, 2018, 359(6382): 1366-1370.
[12]	Galluzzi L, Chan TA, Kroemer G, et al.The hallmarks of successful anticancer immunotherapy [J]. Sci Transl Med, 2018, 10(459): eeat 7807.
[13]	Uzbeck MH, Almeida FA, Sarkiss MG, et al. Management of Malignant Pleural Effusions [J]. Adv Ther, 2010, 27(6): 334-347.
[14]	Zhang C, Zhang Z, Wang L, et al. Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies [J]. Int Immunopharmacol, 2017, 51: 57-65.
[15]	Mu XY. Success in establishing the MSHA-positive Pseudomonas aeruginosa fimbrial strain [J]. J Microbiol, 1986, 26(2): 176-179.
[16]	Lavoie EG, Wangdi T, Kazmierczak BI. Innate immune responses to Pseudomonas aeruginosa infection [J]. Microbes Infect, 2011, 13(14-15): 1133-1145.
[17]	Cai C, Chen W, Miao D, et al. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells [J]. Acta Haematol, 2014, 132 (1): 5-9.
[18]	Liu ZB, Hou YF, Min-Dong, et al. PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines [J]. J Cell Biochem, 2009, 108(1): 195-206.
[19]	Xu WH, Liu ZB, Hou YF, et al. Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer [J]. BMC Cancer, 2014, 14: 273.
[20]	Wei Y, Liu D, Jin X, et al. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62 [J]. Cancer Med, 5(12): 3520-3531.
[21]	Liu J, Duan X. PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells [J]. Cancer Cell Int, 2017, 17: 76.
[22]	Li T, Dong ZR, Guo ZY, et al. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway [J]. Liver Int, 2015, 35(4): 1416-1429.
[23]	Li Z, Hao D, Zhang H, et al. A clinical study on PA-MSHA vaccine used for adjuvant therapy of lymphoma and lung cancer [J]. J West China Univ Med Sci, 2000, 31(3): 334-337.
[24]	沈娣, 王腾, 杭晓声, 等. 铜绿假单胞菌注射液联合化疗治疗晚期胃癌的临床观察[J].中南药学, 2011, 9(7): 548-551.

?		铜绿组（n=31）	顺铂组（n=18）	χ²值	P值
性别		?	?	2.002	0.157
?	男	15	5	?	?
?	女	16	13	?	?
年龄		?	?	2.942	0.086
?	≤60岁	8	9	?	?
?	>60岁	23	9	?	?

?		铜绿组（n=31）	顺铂组（n=18）	χ²值	P值
性别		?	?	2.002	0.157
?	男	15	5	?	?
?	女	16	13	?	?
年龄		?	?	2.942	0.086
?	≤60岁	8	9	?	?
?	>60岁	23	9	?	?

观察指标		铜绿组（n=31）	顺铂组（n=18）	χ²值	P值
疗效		?	?	5.118	0.024
?	有效	19	5	?	?
?	无效	12	13	?	?
生活质量改善		?	?	?	?
?	有	22	7	6.586	0.028
?	无	9	11	?	?

观察指标		铜绿组（n=31）	顺铂组（n=18）	χ²值	P值
疗效		?	?	5.118	0.024
?	有效	19	5	?	?
?	无效	12	13	?	?
生活质量改善		?	?	?	?
?	有	22	7	6.586	0.028
?	无	9	11	?	?

特征		铜绿组（n=31）	顺铂组（n=18）	χ²值	P值
发热		?	?	4.250	0.039
?	无	19	16	?	?
?	有	12	2	?	?
腹痛		?	?	8.430	0.004
?	无	30	12	?	?
?	有	1	6	?	?
腹腔感染		?	?	3.591	0.058
?	无	31	16	?	?
?	有	0	2	?	?
骨髓抑制		?	?	--	--
?	无	31	18	?	?
?	有	0	0	?	?

Please choose a citation manager

Content to export